Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Stock Quote Today & Recent News Nexalin Technologies Inc NXL

Nexalin Technology, Inc., a medical device company, designs and develops neurostimulation products for the treatment of mental health in the United States and China. The company offers Generation 1, an easy-to-administer medical device which utilizes bioelectronic medical technology to treat anxiety, insomnia, and depression without the need for drugs or psychotherapy; and Generation 2 and... see more

Current News (NDAQ:NXL)

Nexalin Announces Pivotal HALO(TM) Clarity Trial to Support Planned De Novo FDA Submission Targeting Multi-Billion-Dollar Insomnia Market

GlobeNewswire February 24, 2026

Nexalin Participates in and Commends Recent Congressional Momentum Supporting Deep Brain Neurostimulation Research for Veterans and Neurological Disorders

GlobeNewswire February 23, 2026

Nexalin Launches NeuroCare®, an AI-Driven Virtual Clinic Designed to Transform Access for Patients with Alzheimer's, Mood Disorders, TBI & PTSD Care

GlobeNewswire February 5, 2026

Nexalin Highlights its Expanding Body of Peer-Reviewed Neuroimaging Research Confirming its DIFS(TM) Technology as the Leader in Evidenced-Based Non-Invasive Brain Stimulation

GlobeNewswire February 2, 2026

Nexalin Technology Receives Nasdaq Listing Status Notification

GlobeNewswire January 23, 2026

Published Peer-Reviewed Study Demonstrates Nexalin's DIFS(TM) Neurostimulation Improves Attention and Normalizes Brain Activity in Patients with ADHD

GlobeNewswire January 14, 2026

Nexalin Technology Completes FDA Q-Submission Meeting for Gen-2 SYNC(TM) Neurostimulation Console in Alzheimer's Disease Program

GlobeNewswire December 3, 2025

Join Nexalin Technology's Exclusive Live Investor Webinar and Q&A Session on December 4

GlobeNewswire December 2, 2025

Nexalin's 15 Milliamp Neurostimulation Device Demonstrates Promising Results in Treating Gambling Disorder with Alcohol Use Comorbidity

GlobeNewswire November 18, 2025

Opinion & Analysis (NDAQ:NXL)

No current opinion is available.

Bullboard Posts (NDAQ:NXL)

Nexalin Technology, Inc. (NXL): Innovative Neurostimulation

http://beyondspx.com/2024/08/01/nexalin-technology-inc-nxl-innovative-neurostimulation-solutions-poised-for-growth/
MikeTester - August 2, 2024

BUY BUY BUY BUY BUY

Next multi bagger
Nibinator - June 22, 2024

NXL..... I was wrong

Lo Siento !!!!!
Iseneschal - June 21, 2024

NXL.....After all....it is "Fryday"

sec.gov/Archives/edgar/data/1527352/000182912624003705/nexalintech_s1.htm
Iseneschal - June 21, 2024

NXL..... Go ahead.....I dare ya

P.O set up Wait for the announcement
Iseneschal - June 21, 2024

Boom

eom
Cobalt - June 21, 2024

Podcasts